# Menopause Hormones: Symptoms, Prevention and Testosterone

Systemic menopausal hormone therapy reduces bothersome hot flushes; this established symptom benefit does not demonstrate dementia or cardiovascular prevention, and testosterone needs its own indication-specific evidence.

The registered primary-subclaim rule assigns Ζ with High confidence from SC2: systemic menopausal hormone therapy causes vasomotor symptom relief in baseline symptomatic women. Endocrine–thermoregulatory contribution is separately rated Ζ, prevention Β, testosterone for HSDD Ε, and broader testosterone enhancement Γ. Weakest-link would return Β for an unregistered conjunction of these different indications; primary-subclaim and scope-matched return Ζ. The symptom grade does not establish preventive or testosterone efficacy.

Symptom efficacy is replicated across selected systemic regimens and symptomatic cohorts, with meaningful baseline age/menopause-stage and dose boundaries. The review does not designate people as in scope because they responded. Rare serious harms, years of contemporary transdermal exposure, incident dementia and all-women testosterone claims remain separate. A trial selected for symptoms cannot establish prevention in asymptomatic users, and a prevention trial cannot be read as a universal ban on symptom treatment.